Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle
- 21 January 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 19 (4), 415-431
- https://doi.org/10.1517/13543770802600698
Abstract
Background: Severe acute respiratory syndrome (SARS) coronavirus emerged from an animal reservoir in 2002 and has the potential to reemerge, as shown by the occurrence of non-laboratory-associated new cases in the winter of 2003. In the absence of a vaccine, broad spectrum anticoronaviral medications are needed. Objective: Anticoronavirals targeting viral entry were reviewed in part I. Here we review anticoronaviral therapies directed against the intracellular life cycle, with an emphasis on allowed patents and pending patents. Method: The published literature, in particular, patent publications is searched for relevant documents. The information is organized and critiqued. Results/conclusion: Many promising anticoronaviral strategies are identified. Monoclonal antibodies, protease inhibitors, interferon-based drugs and nucleic-acid based antivirals are most advanced, each having its own advantages and disadvantages. A multi-pronged approach, keeping all venues open, is advocated.Keywords
This publication has 100 references indexed in Scilit:
- A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replicationProceedings of the National Academy of Sciences of the United States of America, 2008
- Structure of the Main Protease from a Global Infectious Human Coronavirus, HCoV-HKU1Journal of Virology, 2008
- Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cellsBiochemical and Biophysical Research Communications, 2008
- Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated StrainJournal of Virology, 2007
- Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome CoronavirusPublished by Elsevier BV ,2007
- Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi MembraneJournal of Virology, 2007
- Long-Range Cooperative Interactions Modulate Dimerization in SARS 3CLproBiochemistry, 2006
- Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication CycleAntimicrobial Agents and Chemotherapy, 2006
- Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzymeProceedings of the National Academy of Sciences of the United States of America, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006